Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 49, 2020 - Issue 2
Submit an article Journal homepage
217
Views
14
CrossRef citations to date
0
Altmetric
Letters

Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis

FPB KroonDepartment of Rheumatology, Leiden University Medical Center, Leiden, The NetherlandsCorrespondence[email protected]
View further author information
,
AC Bay-JensenBiomarker and Research, Nordic Bioscience, Herlev, DenmarkView further author information
,
R WittoekDepartment of Rheumatology, Ghent University Hospital, Ghent, BelgiumView further author information
,
G VerbruggenDepartment of Rheumatology, Ghent University Hospital, Ghent, BelgiumView further author information
,
JS SmolenDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaView further author information
,
M KloppenburgDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The NetherlandsView further author information
&
R RamondaRheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, ItalyView further author information
 show all
Pages 167-168 | Accepted 15 Aug 2019, Published online: 30 Sep 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
"Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis." Scandinavian Journal of Rheumatology, 49(2), pp. 167–168

Acknowledgement

This study was funded by Pfizer.

Disclosure statement

MK reports an unrestricted grant paid to the institution and study medication free of charge from Pfizer (Wyeth) during the conduct of the study, outside the submitted work. MK reports advisory board fees from Levicept, GlaxoSmithKline, AbbVie, Merck, and Pfizer, grants from IMI-EFpIA ApproACH, grants from Pfizer, and other from AbbVie. ACBJ is a full-time employee and holds shares at Nordic Bioscience. The other authors have no potential conflicts of interest to report.

Additional information

Funding

This work was supported by This study was funded by Pfizer

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 171.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.